Price supervisor Stefan Meierhans has demanded that parliament vote in favour of a proposal to introduce a reference price system, which he says could save CHF400 million ($437 million) a year.
The watchdog compared the prices of 20 patent-expired active ingredients with 15 reference countries. It found the average cost of generic drugs to be 165% higher in Switzerland – and 64% more expensive for patented drugs.
It costs five times more to treat a patient with the same drug in Switzerland than in the least expensive countries of Sweden, Denmark and Britain, said Meierhans in a newsletter published on Thursday.
In May, Santésuisse and Interpharma, the umbrella organisations for Swiss insurers and pharmaceutical research companies, also criticised the high price of medicines in Switzerland.
While their report acknowledged the impact of currency exchange rates on the comparative prices, it also called on lawmakers to introduce a reference price system.
More than 20 European countries already have such a system in place that bases insurance reimbursement payments for each active ingredient on the price of the cheapest available generic.
Most Read Swiss Abroad
More
Will a drastic hike in Swiss inheritance tax lead to an exodus of billionaires?
Swiss railways keep breaking passenger traffic records
This content was published on
Following a record in the first quarter, the railways set a new second-quarter record in 2024 with 5.78 billion passenger-kilometres between April and June.
Rents in Switzerland continue to climb as housing shortage persists
This content was published on
Rents in Switzerland continue to rise, a trend further accentuated by stagnant construction activity and population growth.
Swiss scientists develop new method for measuring permafrost
This content was published on
Scientists in Fribourg have developed a new method to measure permafrost, potentially enhancing predictions of rockfalls and landslides.
Italian mountaineer dies after rockfall on the Matterhorn
This content was published on
The man wanted to climb the 4,478-metre peak in canton Valais via the Hörnligrat ridge with a companion as part of a two-man rope team.
This content was published on
Banque Havilland SA, a private bank owned by the family of close friends of Prince Andrew, has begun the process of closing its operations in Switzerland.
Swiss pharmacies face Covid-19 vaccine shortages amid summer wave
This content was published on
Switzerland is facing a summer wave of Covid-19, with pharmacies and doctors’ surgeries struggling with vaccine shortages.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland remains high price island for drugs
This content was published on
The price of medical drugs in Switzerland remains higher than in other major European markets, especially for generic drugs.
This content was published on
Helsana has also compiled a blacklist of expensive Swiss clinics, with the aim of rewarding clients who stay away from them. Cross-border operations are the latest money-saving strategy from Swiss insurers, eager to put the brakes on ever-increasing healthcare costs. Health costs in Switzerland increased in 2003 by more than four per cent to almost…
This content was published on
Swiss health insurance premiums are to go up again in 2021, but at 0.5% the average hike is milder than the norm over the past decades.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.